DYN — Dyne Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1818794 ·
Last close
$16.02
Market Cap
$3.00B
52W High
$27.31
52W Low
$14.00
ADV30
2,674,730
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -197,074,000 | -193,552,000 | 1,234,802,000 | 913,203,000 | 303,869,000 |
| Jun 2026 | 0 | — | -181,661,000 | -178,556,000 | 994,013,000 | 676,114,000 | 291,862,000 |
| Mar 2026 | 0 | — | -125,276,000 | -120,854,000 | 1,079,950,000 | 753,102,000 | 214,895,000 |
| Dec 2025 | 0 | — | -116,129,000 | -111,955,000 | 1,186,958,000 | 893,369,000 | 214,829,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-564,529,000
Investing CF
$-7,499,000
Financing CF
$914,243,000
CapEx
$-4,232,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.96
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,889,104,000
Inventory
—
Receivables
—
ST Investments
$221,183,000
EBIT TTM
$-586,977,000
Pretax Income TTM
$-604,917,000
Interest Exp TTM
$17,940,000
Analysts
15
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -468,184,000 | -446,214,000 | 1,186,958,000 | 214,829,000 | 972,129,000 | -403,207,000 |
| Dec 2024 | 0 | -343,886,000 | -317,418,000 | 691,234,000 | 61,396,000 | 629,838,000 | -292,369,000 |
| Dec 2023 | 0 | -242,162,000 | -235,937,000 | 165,082,000 | 73,790,000 | 91,292,000 | -188,158,000 |
| Dec 2022 | 0 | -170,962,000 | -168,099,000 | 306,325,000 | 53,961,000 | 252,364,000 | -153,645,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-519,406,000
OpCashFlow TTM
—
Assets (Latest)
$994,013,000
Forward EPS
$-3.31
Max Pain — expiry 2026-12-18
max pain strike: $22.50 · spot: $15.87 · call oi: 3,235 · put oi: 7,755
Expected Move to 2026-12-18:
±$2.83
(17.83%) —
implied range
$13.04 –
$18.70
· ATM straddle on $16.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TLX | Telix Pharmaceuticals Ltd | $3.01B | $8.85 | — |
| XERS | Xeris Biopharma Holdings, Inc. | $3.07B | $16.80 | — |
| ZLAB | Zai Lab Ltd | $2.91B | $23.53 | — |
| BGM | BGM Group Ltd. | $3.09B | $8.13 | — |
| LEGN | Legend Biotech Corp | $3.13B | $16.11 | — |
News headlines (Yahoo Finance, 1h cache)
Dyne Therapeutics to Participate in Upcoming Investor Conference
2026-11-11 12:30 · Yahoo
Is Dyne Therapeutics (DYN) Undervalued After Wider Losses And FDA Priority Review?
2026-11-05 20:13 · Yahoo
Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-05 12:30 · Yahoo
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-22 20:05 · Yahoo
Why Dyne Therapeutics (DYN) Is Back In The Spotlight
2026-10-07 14:12 · Yahoo
Dyne Therapeutics stock rises on positive DM1 trial results
2026-09-29 21:23 · Yahoo
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
2026-09-29 20:05 · Yahoo
Do Dyne Therapeutics’ (DYN) Expanded DM1 Data Presentations Redefine Its Rare-Disease Investment Narrative?
2026-09-17 16:13 · Yahoo
Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes
2026-09-09 15:41 · Yahoo
PepGen Stock Doubles in One Session - Here's Why
2026-11-10 18:47 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.